Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo
Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with <sup>177</sup>Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/11/4/132 |